Adenocarcinoma gastric

13 trials 7 recruiting MedDRA PT
13 Registered trials
7 Recruiting
11 Unique sponsors
19 Unique IMPs
10 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
L Oncology (ATC L) 4
V Various (ATC V) 3
B Haematology (ATC B) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 8 substances
Checkpoint inhibitor (PD-1) 2 substances
Antimetabolite 1 substance
Supportive / rescue 1 substance
Platinum compound 1 substance
Monoclonal antibody (chimeric) 1 substance
Supportive / diluent 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Antibody-drug conjugate (ADC) 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Taxane 1 substance
Phase III: 4 Phase II/III: 1 Phase II: 3 Phase I/II: 1 Phase I: 3 Phase I (First in Human): 1

Filter these 13 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 13 trials

Phase III

4 trials
  • Astellas Pharma Global Development Inc. Commercial
    SODIUM CHLORIDE; ZOLBETUXIMAB
    2024-511365-11-00 6 countries 2018 n=210 Orphan
    Ended
  • Astellas Pharma Global Development Inc. Commercial
    SODIUM CHLORIDE; ZOLBETUXIMAB
    2024-511648-16-00 3 countries 2019 n=108 Orphan
    Ended
  • BeOne Medicines AG Commercial
    TISLELIZUMAB
    2025-522862-58-00 6 countries 2026 n=63
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB
    2023-509595-42-00 8 countries 2017 n=297
    Ended

Phase II/III

1 trial
  • UZ Leuven Academic
    [AL[18F]F]FAPI-74; IOXITALAMATE MEGLUMINE
    2024-512059-19-00 1 country 2025 n=109
    Recruiting

Phase II

3 trials
  • Astellas Pharma Global Development Inc. Commercial
    FLUOROURACIL; FOLINIC ACID; NIVOLUMAB; OXALIPLATIN; ZOLBETUXIMAB
    2024-511649-21-00 2 countries 2018 n=48 Orphan
    Ended
  • AstraZeneca AB Commercial
    AZD0901; RILVEGOSTOMIG; SABESTOMIG; VOLRUSTOMIG
    2024-510977-27-00 1 country 2023 n=8
    Recruiting
  • Institut De Cancerologie De L Ouest Academic
    BEMARITUZUMAB; DOCETAXEL; FLUOROURACIL; LEVOLEUCOVORIN; OXALIPLATIN
    2024-514078-29-00 1 country n=49 Orphan
    Ended

Phase I/II

1 trial
  • Daiichi Sankyo Inc. Commercial
    IFINATAMAB DERUXTECAN
    2023-509632-26-00 9 countries 2025 n=311 Orphan
    Recruiting

Phase I

3 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-509335-60-00 4 countries 2023 n=177
    Recruiting
  • Beigene Ltd. Commercial
    IMP not specified
    2023-505322-34-00 1 country 2024 n=45
    Ended
  • Rigshospitalet Academic
    IMP not specified
    2024-516786-37-00 1 country 2025 n=140
    Recruiting

Phase I (First in Human)

1 trial
  • Salubris Biotherapeutics Inc. Commercial
    JK06
    2024-512421-92-00 2 countries 2025 n=305
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Astellas Pharma Global Development Inc. Commercial 3 Phase II, Phase III 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I 1
Beigene Ltd. Commercial 1 Phase I 0
AstraZeneca AB Commercial 1 Phase II 1
BeOne Medicines AG Commercial 1 Phase III 1
Merck Sharp & Dohme LLC Commercial 1 Phase III 0
Salubris Biotherapeutics Inc. Commercial 1 Phase I (First in Human) 1
Daiichi Sankyo Inc. Commercial 1 Phase I/II 1
Rigshospitalet Academic 1 Phase I 1
UZ Leuven Academic 1 Phase II/III 1
Institut De Cancerologie De L Ouest Academic 1 Phase II 0
New trials by year
2019
1
2023
2
2024
1
2025
4
2026
1
← All indication landscapes